LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 19. (Cancelled)

20. (Currently Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence ~~selected from the group consisting~~ of SEQ ID NO: 38 :¶

~~(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40;¶~~

~~(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;¶~~

~~(c) an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40;¶~~

~~(d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; ¶~~

~~(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and ¶~~

~~(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).~~

21. (Currently Amended) ~~The~~ An isolated nucleic acid molecule comprising a ~~of claim 20, wherein the nucleic acid molecule comprises the~~ nucleotide sequence that is the complement of the nucleic acid sequence of claim 20 ~~of a naturally occurring allelic nucleic acid variant~~.

22. (Currently Amended) The nucleic acid molecule of claim 20, wherein the nucleic acid molecule encodes a polypeptide ~~comprising~~ consisting of the amino acid sequence of SEQ ID NO:38 ~~a naturally occurring polypeptide variant~~.

23. (Cancelled)

24. (Currently Amended) The nucleic acid molecule of claim 20, wherein said nucleic acid molecule comprises a nucleotide sequence of SEQ ID NO: 37 ~~selected from the group consisting of:¶~~

~~(a) a nucleotide sequence selected from the group consisting of SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39;¶~~

~~(b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39, provided that no more than 20% of the nucleotides differ from said nucleotide sequence; ¶~~

~~(c) a nucleic acid fragment of (a); and¶~~

~~(d) a nucleic acid fragment of (b)~~.

25. (Currently Amended) The nucleic acid molecule of claim 20, wherein said nucleic acid molecule, wherein the nucleic acid molecule consists of the nucleic acid sequence of SEQ ID NO: 37 ~~hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39, or a complement of said nucleotide sequence~~.

26. (Cancelled)

27. (Currently Amended) A vector comprising the nucleic acid molecule of ~~claim 26~~ claim 20.

28. (Original) The vector of claim 27, further comprising a promoter operably-linked to said nucleic acid molecule.

29. (Original) A cell comprising the vector of claim 27.

30. – 33. (Cancelled)

34. (Currently Amended) A method for determining the presence or amount of the nucleic acid molecule of ~~claim 16~~ claim 20 in a sample, the method comprising:

(a) providing the sample;

(b) contacting the sample with a probe that binds to said nucleic acid molecule; and

(c) determining the presence or amount of the probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.

35. (Original) The method of claim 34 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

36. (Original) The method of claim 35 wherein the cell or tissue type is cancerous.

37. – 53. (Cancelled)

54. (Original) A pharmaceutical composition comprising the nucleic acid molecule of claim 20 and a pharmaceutically-acceptable carrier.

55. – 56. (Cancelled)

57. (Original) A kit comprising in one or more containers, the pharmaceutical composition of claim 54.

58. – 60. (Cancelled)

61. (Original) A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 20 in a first mammalian subject, the method comprising:

(a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and

(b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;

wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

62. (Original) The method of claim 61 wherein the predisposition is to a cancer.

63. – 64. (Cancelled)